Lüke, J.; Zippel, C.; Tepasse, P.-R.; Lenze, F.; Strauss, M.; Bokemeyer, A.; Buskermolen, J.; Schomacher, T.; Fischer, J.; Trebicka, J.;
et al. Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease. Diseases 2026, 14, 54.
https://doi.org/10.3390/diseases14020054
AMA Style
Lüke J, Zippel C, Tepasse P-R, Lenze F, Strauss M, Bokemeyer A, Buskermolen J, Schomacher T, Fischer J, Trebicka J,
et al. Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease. Diseases. 2026; 14(2):54.
https://doi.org/10.3390/diseases14020054
Chicago/Turabian Style
Lüke, Janina, Clara Zippel, Phil-Robin Tepasse, Frank Lenze, Markus Strauss, Arne Bokemeyer, Joost Buskermolen, Tina Schomacher, Julia Fischer, Jonel Trebicka,
and et al. 2026. "Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease" Diseases 14, no. 2: 54.
https://doi.org/10.3390/diseases14020054
APA Style
Lüke, J., Zippel, C., Tepasse, P.-R., Lenze, F., Strauss, M., Bokemeyer, A., Buskermolen, J., Schomacher, T., Fischer, J., Trebicka, J., & Vollenberg, R.
(2026). Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease. Diseases, 14(2), 54.
https://doi.org/10.3390/diseases14020054
